SPMs exert anti-inflammatory and pro-resolving effects through positive allosteric modulation of the prostaglandin EP4 receptor.


Journal

Proceedings of the National Academy of Sciences of the United States of America
ISSN: 1091-6490
Titre abrégé: Proc Natl Acad Sci U S A
Pays: United States
ID NLM: 7505876

Informations de publication

Date de publication:
08 Oct 2024
Historique:
medline: 4 10 2024
pubmed: 4 10 2024
entrez: 4 10 2024
Statut: ppublish

Résumé

Inflammation is a protective response to pathogens and injury. To be effective it needs to be resolved by endogenous mechanisms in order to avoid prolonged and excessive inflammation, which can become chronic. Specialized pro-resolving mediators (SPMs) are a group of lipids derived from omega-3 fatty acids, which can induce the resolution of inflammation. How SPMs exert their anti-inflammatory and pro-resolving effects is, however, not clear. Here, we show that SPMs such as protectins, maresins, and D-series resolvins function as biased positive allosteric modulators (PAM) of the prostaglandin E

Identifiants

pubmed: 39365815
doi: 10.1073/pnas.2407130121
doi:

Substances chimiques

Receptors, Prostaglandin E, EP4 Subtype 0
Anti-Inflammatory Agents 0
Dinoprostone K7Q1JQR04M

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

e2407130121

Subventions

Organisme : Deutsche Forschungsgemeinschaft (DFG)
ID : CRC1039 204083920

Déclaration de conflit d'intérêts

Competing interests statement:The authors declare no competing interest.

Auteurs

Mohamad Wessam Alnouri (MW)

Department of Pharmacology, Max Planck Institute for Heart and Lung Research, Bad Nauheim 61231, Germany.

Kenneth Anthony Roquid (KA)

Department of Pharmacology, Max Planck Institute for Heart and Lung Research, Bad Nauheim 61231, Germany.

Rémy Bonnavion (R)

Department of Pharmacology, Max Planck Institute for Heart and Lung Research, Bad Nauheim 61231, Germany.

Haaglim Cho (H)

Department of Pharmacology, Max Planck Institute for Heart and Lung Research, Bad Nauheim 61231, Germany.

Jan Heering (J)

Fraunhofer Institute for Translational Medicine and Pharmacology and Fraunhofer Cluster of Excellence for Immune Mediated Diseases, Frankfurt am Main 60596, Germany.

Jeonghyeon Kwon (J)

Department of Pharmacology, Max Planck Institute for Heart and Lung Research, Bad Nauheim 61231, Germany.

Yannick Jäger (Y)

Department of Pharmacology, Max Planck Institute for Heart and Lung Research, Bad Nauheim 61231, Germany.

ShengPeng Wang (S)

Cardiovascular Research Center, School of Basic Medical Sciences, Xi'an Jiaotong University Health Science Center, Xi'an 710061, China.

Stefan Günther (S)

Max Planck Institute for Heart and Lung Research, Deep Sequencing Platform, Bad Nauheim 61231, Germany.

Nina Wettschureck (N)

Department of Pharmacology, Max Planck Institute for Heart and Lung Research, Bad Nauheim 61231, Germany.
Center for Molecular Medicine, Goethe University Frankfurt, Frankfurt 60590, Germany.
Excellence Cluster Cardiopulmonary Institute (CPI), Bad Nauheim Bad 61231, Germany.
German Center for Cardiovascular Research (DZHK), Rhine-Main site, Bad Nauheim 61231, Germany.

Gerd Geisslinger (G)

Fraunhofer Institute for Translational Medicine and Pharmacology and Fraunhofer Cluster of Excellence for Immune Mediated Diseases, Frankfurt am Main 60596, Germany.
Institute of Clinical Pharmacology, Goethe University, Frankfurt am Main 60590, Germany.

Robert Gurke (R)

Fraunhofer Institute for Translational Medicine and Pharmacology and Fraunhofer Cluster of Excellence for Immune Mediated Diseases, Frankfurt am Main 60596, Germany.
Institute of Clinical Pharmacology, Goethe University, Frankfurt am Main 60590, Germany.

Christa E Müller (CE)

Pharmaceutical Institute, Pharmaceutical & Medicinal Chemistry, University of Bonn, Bonn 53121, Germany.
PharmaCenter Bonn, University of Bonn, Bonn 53121, Germany.

Ewgenij Proschak (E)

Fraunhofer Institute for Translational Medicine and Pharmacology and Fraunhofer Cluster of Excellence for Immune Mediated Diseases, Frankfurt am Main 60596, Germany.
Institute of Pharmaceutical Chemistry, Goethe University Frankfurt, Frankfurt 60438, Germany.

Stefan Offermanns (S)

Department of Pharmacology, Max Planck Institute for Heart and Lung Research, Bad Nauheim 61231, Germany.
Center for Molecular Medicine, Goethe University Frankfurt, Frankfurt 60590, Germany.
Excellence Cluster Cardiopulmonary Institute (CPI), Bad Nauheim Bad 61231, Germany.
German Center for Cardiovascular Research (DZHK), Rhine-Main site, Bad Nauheim 61231, Germany.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH